Non-absorbable implants better in the long-term

Article

The use of implants in deep sclerectomy enhances success rates and lowers the need for postoperative medications, according to Petr Strnad, MD and colleagues from the Masaryk University, Czech Republic.

The use of implants in deep sclerectomy enhances success rates and lowers the need for postoperative medications, according to Petr Strnad, MD and colleagues from the Masaryk University, Czech Republic.

They conducted a retrospective review of 86 eyes of 56 patients who had undergone deep sclerectomy, with at least five-years follow-up. The patients were divided into three groups according to the type of surgery. The first group underwent deep sclerectomy without implant (40 eyes, 26 patients); the second underwent deep sclerectomy with an absorbable collagen implant (24 eyes, 16 patients) and the third group underwent deep sclerectomy with a non-absorbable implant (22 eyes, 14 patients).

The average preoperative intraocular pressure (IOP) of the three groups was recorded at 25.3, 25.9 and 23.7 mmHg, respectively and the number of anti-glaucoma medications was 3.1, 3.2 and 3.4. Mean follow-up time was 81.6, 78 and 69.8 months, respectively.

Average IOP, at the end of the follow-up period, was 17.25 mmHg for the group with no implant, 16.7 mmHg for those with the absorbable implant and 16.5 mmHg for those with the non-absorbable implant. The number of anti-glaucoma medications was 2.1, 1.6 and 0.8, respectively.

The researchers discovered that patients who received an implant during surgery achieved better outcomes than those who did not and that non-absorbable implants, in particular, offered better long-term IOP compensation than absorbable implants.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
© 2025 MJH Life Sciences

All rights reserved.